deltatrials
Completed PHASE1 NCT00097747

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

A Phase 1, Double-blind, Placebo-controlled, Dose Escalation Study of the Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

Sponsor: Affymax

Conditions Anemia Cancer Chronic Kidney Disease Chronic Renal Failure
Interventions Placebo peginesatide
Updated 6 times since 2017 Last updated: Dec 19, 2012 Started: Aug 31, 2004 Primary completion: Jan 31, 2005 Completion: Jan 31, 2005

A PHASE1 clinical study on Anemia and Cancer, this trial is completed. The trial is conducted by Affymax and has accumulated 6 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Affymax
Data source: Affymax

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • London, United Kingdom